a partner for what? their next drug trial is already scheduled...they have enough cash to sustain themselves until then. the next trial involves what...30 patients? will take them a full year to release more data?
so what other catalysts does that leave us with?
but what will rnn run on to get to 3? the next trial data for the recent announcement wont be available until next year...what else does rnn have in stock that could maintain the pps
trial data wont be available till mid-2015...so what other catalysts r there? i too neglected to sell, my average is .50, but will likely sell tomorrow.
yeah and how great as sirus done in the past 3 years..it has hovered between 1.5 and 3...no chance it will ever rise significantly because it is so diluted. and comparing a company that actually makes money and churns a significant profit to a small cap biotech is dubious at best
uh...market manipulation. no, just traders taking profits. this is so typical in biotech. few biotechs are truly victim of a coordinated market manipulation. traders are responsible for most of the volume, and OTC are not considered hugely valuable by institutions because it goes both ways.
we hear this in all MB...we heard it in zlcs, we hear it all the time at ino. most traders are not longs...and longs should care about these ups and downs...unless ur secretly traders
elite also has 500 million outstanding shares, which is a problem. company will likely do an RS at some point if they become more successful. so i think some people may be holding out until then.
why bad timing? ino is an incredibly bipolar stock and i wouldnt be surprised if it goes below 2 before the middle of the year.
shorts are always liars...what? most of the lies come from pumpers. no, this is true. look up institutional investors. who else would be responsible for the volume? longs?
sabby management LLC purchased over 1 million shares on 12/31/13, right before oncs released their interim data.
who believes oncs leaked their data to their institutional investors? im glad they did...kind of, but this is so shady. i would like to see some more thoughtful posts discussing oncs investors and shareholders. what we will really see in 2014...can oncs hit 5-6...which would push its MC above 1 billion?
what other biotechs are less speculative? all biotechs are speculative. every single one. oncs technology has been validated by ino...maybe in the long run the device blows up....but oncs could easily hit 4-5 before delivering anything.
i know this is a great stock, but if we see .30-.40 while we wait for the next update...that is a huge loss. so this is why i am curious as to when we will see the next hard data. i know tuesday oncs will have the conference, but what are the chances oncs will anounce scheduled dates for next data? the latest we can expect new data is mid 2014...and we could see pps fall below .40 while we wait.
so honestly, when are the next catalysts? i thought we would see some data this month, but now all i see is the next conference. i imagine if oncs doesnt release anyting meaningful we will see some profit taking...
also have to consider oncs future is linked with vgx-3100. what thing that concerns me is while inos pipeline is significant, a lot of the studies have either been discontinued or stalled. if vgx is not successful, ino could be done for good.
nah, 6 is peak if vgx meets primary endpoints. if ino didnt dilute so much more than 6 could have been possible. but 3+ billion market cap with one positive study...unlikely.
if u bought ino below 1.000, good for u. but right now, at 2.50ish, the upside for ino, at least in the medium term, is not as good as oncs if u buy now. oncs could very well be 2-3 dollars by the end of the year, but i dont see ino being more than 6 by the end of the year, even if the trial in mid 2014 goes well. ino is dominated by traders, and the longs dont care because they have such low averages. theyll sit on ino till it is 50 or 60 5 years from now.
if u dont have a lot of money, oncs will provide u a much better return.